ArticleOncology and therapy2025

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast.

Balazs Halmos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.